TRCT
ARTL icon

Tower Research Capital (TRC)’s Artelo Biosciences ARTL Stock Holding History

Tower Research Capital (TRC)’s Portfolio ARTL Stock Details ARTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.45K Buy
937
+623
+198% +$16K ﹤0.01% 4025
2026
Q1 		$21.4K Buy
314
+244
+349% +$10.4K ﹤0.01% 3437
2025
Q4 		$2.32K Buy
+70
New +$4.89K ﹤0.01% 4554
2025
Q3 		– Sell
-17
Closed -$5.93K – 5212
2025
Q2 		$5.93K Sell
17
-7
-29% -$1.17K ﹤0.01% 4139
2025
Q1 		$3.42K Hold
24
– – ﹤0.01% 4415
2024
Q4 		$4.05K Sell
24
-8
-25% -$1.45K ﹤0.01% 4530
2024
Q3 		$5.8K Sell
32
-4
-11% -$824 ﹤0.01% 4216
2024
Q2 		$7.8K Buy
36
+6
+20% +$1.35K ﹤0.01% 4425
2024
Q1 		$7.21K Hold
30
– – ﹤0.01% 4242
2023
Q4 		$6.72K Buy
30
+17
+131% +$3.77K ﹤0.01% 4705
2023
Q3 		$3.13K Sell
13
-16
-55% -$4.8K ﹤0.01% 5049
2023
Q2 		$9.26K Buy
29
+4
+16% +$1.31K ﹤0.01% 4311
2023
Q1 		$10K Buy
25
+15
+150% +$6.85K ﹤0.01% 4323
2022
Q4 		$5K Buy
10
+2
+25% +$939 ﹤0.01% 4830
2022
Q3 		$4K Buy
8
+6
+300% +$4.35K ﹤0.01% 5223
2022
Q2 		$2K Sell
2
-6
-75% -$5.31K ﹤0.01% 5507
2022
Q1 		$9K Buy
8
+6
+300% +$6.2K ﹤0.01% 4430
2021
Q4 		$3K Sell
2
-2
-50% -$3.56K ﹤0.01% 5414
2021
Q3 		$8K Buy
4
+3
+300% +$6.86K ﹤0.01% 4517
2021
Q2 		$4K Hold
1
– – ﹤0.01% 4791
2021
Q1 		$2K Buy
+1
New +$3.85K ﹤0.01% 4996
2020
Q3 		– Hold
0
– -$1K – 4808
2020
Q2 		– Hold
0
– – – 4580
2019
Q4 		– Hold
0
– -$1K – 3503
2019
Q3 		– Hold
0
– – – 3814
2019
Q2 		– Hold
0
– – – 3640

Other funds holding ARTL

Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SG
StoneX Group New York $2.48B AUM 33.54% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
RIL
Rothschild Investment LLC Chicago, Illinois $2.68B AUM 34.39% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return
DB
Danske Bank Copenhagen K, Denmark $50.6B AUM 42.84% 1-Year Est. Return

Tower Research Capital (TRC)'s ARTL Position: Q2 2026 in Review

Tower Research Capital (TRC) increased its Artelo Biosciences (ARTL) stake by 198% in Q2 2026, buying an estimated $16K and bringing the position to 937 shares worth $9.45K. The position accounts for ﹤0.01% of the portfolio, ranked #4025.

Tower Research Capital (TRC) first reported a position in ARTL in Q1 2021 and has held it in 21 quarters since. The position peaked at $21.4K in Q1 2026. 7 funds tracked by Wall St. Rank hold ARTL as of Q2 2026.

  • Tower Research Capital (TRC) held 937 shares of Artelo Biosciences worth $9.45K as of Q2 2026.
  • Tower Research Capital (TRC) bought 623 Artelo Biosciences shares in Q2 2026, an estimated $16K.
  • Artelo Biosciences made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #4025 holding.
  • Tower Research Capital (TRC) first reported a position in Artelo Biosciences in Q1 2021 and has held it in 21 quarters since.
  • Tower Research Capital (TRC)'s Artelo Biosciences position peaked at $21.4K in Q1 2026.
  • 7 funds tracked by Wall St. Rank held Artelo Biosciences as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.